Onyx Pharmaceuticals, Inc. (ONXX)
-NasdaqGS 95.23 
0.97(1.01%) May 24, 4:00PM EDT
| Prev Close: | 96.20 |
|---|
| Open: | 95.66 |
|---|
| Bid: | 0.10 x 100 |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 109.76 |
|---|
| Beta: | 1.86 |
|---|
| Next Earnings Date: | 2-Aug-13 |
|---|
| Day's Range: | 94.00 - 96.07 |
|---|
| 52wk Range: | 41.26 - 101.57 |
|---|
| Volume: | 464,281 |
|---|
| Avg Vol (3m): | 1,187,780 |
|---|
| Market Cap: | 6.93B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -2.47 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Aveo slumps as Astellas pares cancer drug supportAP(Fri, May 24)
- Onyx Pharmaceuticals Inc. Stock Hold Recommendation Reiterated (ONXX)at TheStreet(Fri, May 24)
- 5 Stocks Raising The Drugs Industry Higherat TheStreet(Thu, May 23)
- ONYX PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a VoEDGAR Online(Thu, May 23)
- Onyx Pharmaceuticals, Inc. Presents at UBS Global Healthcare Conference, May-21-2013 10:30 AMat Seeking Alpha(Tue, May 21)
- Onyx Pharmaceuticals Inc. (ONXX): Today's Featured Drugs Laggardat TheStreet(Tue, May 21)
- Onyx Pharmaceuticals Announces Data Presentations at the 18th Congress of the European Hematology AssociationMarketwired(Tue, May 21)
- Will ASCO Unlock Big Value in This Cancer Drug Class?at Motley Fool(Sat, May 18)
- A Portfolio Construction Strategy with an Emphasis on High-Innovation, Breakthrough Biotech and Pharmaceutical CompaniesWall Street Transcript(Thu, May 16)
- Onyx Pharmaceuticals Announces Data Presentations at 49th American Society of Clinical Oncology Annual MeetingMarketwired(Wed, May 15)
- Aveo Screwed Up but Its Kidney Cancer Drug Is Realat TheStreet(Wed, May 15)
- ONYX PHARMACEUTICALS INC FinancialsEDGAR Online Financials(Tue, May 14)
- Wider-than-Expected Loss at ChemoCentryxZacks(Tue, May 14)
- 3 Earnings Reports That Caught My Attention Last Weekat Motley Fool(Mon, May 13)
- These 5 Stocks Saw Trading Price Swings This Past Week Post Earningsat Wall St. Cheat Sheet(Sun, May 12)
Key Statistics
| Forward P/E (1 yr): | 173.15 |
|---|
| P/S (ttm): | 16.06 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -1.72 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.45 |
|---|
| Mean Recommendation*: | 1.7 |
|---|
| PEG Ratio (5 yr expected): | -1.26 |
|---|
Business Summary
Onyx Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies that target the molecular mechanisms that cause cancer in the United States and internationally.
View More